The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
AOL INC | COM | 00184X105 | 5,949 | 128,850 | SH | SOLE | 128,850 | 0 | 0 | ||
BIOMARIN PHARMACEUTICAL INC | COM | 09061G101 | 8,302 | 91,840 | SH | SOLE | 91,840 | 0 | 0 | ||
BLUEBIRD BIO INC | COM | 09609G100 | 13,518 | 147,380 | SH | SOLE | 147,380 | 0 | 0 | ||
GILEAD SCIENCES INC | COM | 375558103 | 12,807 | 135,870 | SH | SOLE | 135,870 | 0 | 0 | ||
GW PHARMACEUTICALS PLC | ADS | 36197T103 | 9,085 | 134,230 | SH | SOLE | 134,230 | 0 | 0 | ||
INFOBLOX INC | COM | 45672H104 | 30,232 | 1,495,906 | SH | SOLE | 1,495,906 | 0 | 0 | ||
KITE PHARMA INC | COM | 49803L109 | 21,101 | 365,900 | SH | SOLE | 365,900 | 0 | 0 | ||
OCULAR THERAPEUTIX INC | COM | 67576A100 | 1,749 | 74,380 | SH | SOLE | 74,380 | 0 | 0 | ||
OREXIGEN THERAPEUTICS INC | COM | 686164104 | 11,459 | 1,891,000 | SH | SOLE | 1,891,000 | 0 | 0 | ||
PUMA BIOTECHNOLOGY INC | COM | 74587V107 | 10,411 | 55,005 | SH | SOLE | 55,005 | 0 | 0 | ||
RALLY SOFTWARE DEV CORP | COM | 751198102 | 13,230 | 1,163,626 | SH | SOLE | 1,163,626 | 0 | 0 | ||
RINGCENTRAL INC | CL A | 76680R206 | 2,408 | 161,424 | SH | SOLE | 161,424 | 0 | 0 | ||
SALESFORCE COM INC | COM | 79466L302 | 7,590 | 127,970 | SH | SOLE | 127,970 | 0 | 0 | ||
SYNAGEVA BIOPHARMA CORP | COM | 87159A103 | 1,428 | 15,390 | SH | SOLE | 15,390 | 0 | 0 | ||
ULTRAGENYX PHARMACEUTICAL IN | COM | 90400D108 | 3,420 | 77,940 | SH | SOLE | 77,940 | 0 | 0 |